{
  "abstract": "Background High-grade neuroendocrine neoplasms (NENs), including poorly differentiated neuroendocrine carcinomas (NECs) and well-differentiated grade 3 neuroendocrine tumors (NETs), are aggressive malignancies with limited effective treatment options. Immune checkpoint inhibitors (ICIs) have demonstrated limited clinical activity in these tumors. Seneca Valley Virus (SVV-001) is a novel oncolytic RNA virus that has shown synergistic activity with ICIs in preclinical models. Additionally, SVV-001 has been observed to reverse CPI resistance in vivo, supporting its evaluation in combination with nivolumab and ipilimumab.Methods This is an investigator-initiated, phase 1, dose-escalation and cohort-expansion study evaluating intratumoral SVV-001 in combination with nivolumab and ipilimumab in patients with histologically confirmed poorly differentiated NEC or well-differentiated grade 3 NET. The trial was activated in March 2025, with patient enrollment currently ongoing and a target of up to 36 patients. A standard 3+3 dose-escalation design is being employed to determine the recommended phase 2 dose (RP2D). Following dose escalation, an expansion cohort will further evaluate safety and preliminary signals of activity. Tumor endothelial marker 8 (TEM8), a potential biomarker of SVV-001 sensitivity, will be assessed as part of correlative studies. The Clinical Trial Identifier is NCT06889493Trial Registration Clinical Trial Identifier: NCT06889493Ethics Approval The study was approved by the institutional review boards and conducted in accordance with International Conference on Harmonization Good Clinical Practice Guidelines (ICH-GCP) and the Declaration of Helsinki. Study participation is voluntary and all enrolled patients have signed a consent form before taking part in the trial.",
  "authors": [
    {
      "affiliations": [
        "University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA"
      ],
      "name": "Aman Chauhan"
    },
    {
      "affiliations": [
        "University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA"
      ],
      "name": "Isildinha M Reis"
    },
    {
      "affiliations": [
        "University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA"
      ],
      "name": "Chinmay T Jani"
    },
    {
      "affiliations": [
        "University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA"
      ],
      "name": "Rakhi Modak"
    },
    {
      "affiliations": [
        "University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA"
      ],
      "name": "Daniel Bilbao"
    },
    {
      "affiliations": [
        "Seneca Therapeutics, Inc., Blue Bell, PA, USA"
      ],
      "name": "Paul Hallenbeck"
    },
    {
      "affiliations": [
        "Seneca Therapeutics, Inc., Blue Bell, PA, USA"
      ],
      "name": "Hung Trinh"
    },
    {
      "affiliations": [
        "University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA"
      ],
      "name": "Jaime R Merchan"
    },
    {
      "affiliations": [
        "University of Miami, Miller School of Medicine, Miami, FL, USA"
      ],
      "name": "Gilberto Lopes"
    },
    {
      "affiliations": [
        "University of Miami, Coral Gables, FL, USA"
      ],
      "name": "Peter Hosein"
    }
  ],
  "title": "597 A phase 1 trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with high grade neuroendocrine neoplasms",
  "uid": "14e5c462-3acd-5f09-b094-cff70c1e2b52"
}